MX337516B - Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer. - Google Patents
Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer.Info
- Publication number
- MX337516B MX337516B MX2012000441A MX2012000441A MX337516B MX 337516 B MX337516 B MX 337516B MX 2012000441 A MX2012000441 A MX 2012000441A MX 2012000441 A MX2012000441 A MX 2012000441A MX 337516 B MX337516 B MX 337516B
- Authority
- MX
- Mexico
- Prior art keywords
- bond
- cancer
- treatment
- thiazolidin
- derivatives
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical class O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
De acuerdo con la invención se provee un compuesto de la fórmula (I) en donde: A representa C(N-W-D) o S; B representa S o C(-NH W-D); cuando A representa C(=N-W-D) y B representa S, entonces el enlace entre B y el átomo de NH es un enlace sencillo; o cuando A representa S y B representa C(-NH-W-D), entonces el enlace entre B y el átomo de NH es un enlace doble; X representa -Q-[CRxRY]n-; W representa [CRXRY]m o -C(O)- [CRXR]p-, Q representa un enlace, -N(Ra), -S-, u -O-; A1 a A5 representan, respectivamente, C(R1), C(R2), C(R3), C(R4) y C(R5), o alternativamente hasta dos de A1 a A5 pueden representar independientemente N; D representa fenilo, piridilo o pirimidinilo, sustituido opcionalmente con uno o más grupos R6 dichos compuestos son útiles en el tratamiento del cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21373509P | 2009-07-08 | 2009-07-08 | |
| PCT/GB2010/001315 WO2011004162A2 (en) | 2009-07-08 | 2010-07-08 | Compounds useful as medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012000441A MX2012000441A (es) | 2012-04-19 |
| MX337516B true MX337516B (es) | 2016-03-09 |
Family
ID=43086401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012000441A MX337516B (es) | 2009-07-08 | 2010-07-08 | Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9162994B2 (es) |
| EP (1) | EP2451794B1 (es) |
| JP (1) | JP5982281B2 (es) |
| KR (1) | KR101765957B1 (es) |
| CN (1) | CN102596923B (es) |
| AU (1) | AU2010270030B2 (es) |
| BR (1) | BR112012000370B1 (es) |
| CA (1) | CA2767291C (es) |
| DK (1) | DK2451794T3 (es) |
| EA (1) | EA026674B1 (es) |
| ES (1) | ES2567753T3 (es) |
| HR (1) | HRP20160353T1 (es) |
| HU (1) | HUE027263T2 (es) |
| IL (1) | IL216723A (es) |
| ME (1) | ME02443B (es) |
| MX (1) | MX337516B (es) |
| NZ (1) | NZ597075A (es) |
| PL (1) | PL2451794T3 (es) |
| RS (1) | RS54718B1 (es) |
| SG (1) | SG177558A1 (es) |
| SI (1) | SI2451794T1 (es) |
| SM (1) | SMT201600225B (es) |
| WO (1) | WO2011004162A2 (es) |
| ZA (1) | ZA201108901B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100931145B1 (ko) * | 2008-07-04 | 2009-12-10 | 현대자동차주식회사 | 조정식 킥 다운 스위치의 조작기구 |
| WO2013108026A1 (en) | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ａｍｐｋを活性化させるインダゾール化合物 |
| GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| PL3571193T3 (pl) | 2017-01-23 | 2022-04-25 | Cadent Therapeutics, Inc. | Modulatory kanału potasowego |
| KR20240026521A (ko) | 2017-03-23 | 2024-02-28 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| EP3870291A1 (en) | 2018-10-22 | 2021-09-01 | Cadent Therapeutics, Inc. | Crystalline forms of potassium channel modulators |
| WO2020095010A1 (en) | 2018-11-05 | 2020-05-14 | Balticgruppen Bio Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
| CN109879808B (zh) * | 2019-03-05 | 2020-10-16 | 北京工业大学 | 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途 |
| GB201910092D0 (en) | 2019-07-15 | 2019-08-28 | Balticgruppen Bio Ab | New formulations |
| GB201910093D0 (en) | 2019-07-15 | 2019-08-28 | Balticgruppen Bio Ab | New formulations |
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
| GB202015585D0 (en) * | 2020-10-01 | 2020-11-18 | Betagenon Bio Ab | New compounds |
| GB202100352D0 (en) * | 2021-01-12 | 2021-02-24 | Balticgruppen Bio Ab | New methods |
| GB202112529D0 (en) | 2021-09-02 | 2021-10-20 | Betagenon Bio Ab | New compounds |
| WO2025017194A1 (en) | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler |
| WO2025017193A1 (en) | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods of treating cardiomyopathy induced by metabolic inflexibility |
| WO2025027205A1 (en) | 2023-08-03 | 2025-02-06 | Betagenon Ab | Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide |
| WO2025252672A1 (en) | 2024-06-03 | 2025-12-11 | Betagenon Ab | Use of tryptophan and metabolites thereof as biomarkers for treatment methods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093624A (en) | 1977-01-31 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 1,2,4-Thiadiazolidine-3,5-dione |
| MXPA02011079A (es) | 2000-05-11 | 2004-08-19 | Consejo Superior Investigacion | Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3. |
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| WO2006045581A1 (en) | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
| US20090156644A1 (en) | 2005-07-21 | 2009-06-18 | Jacob Westman | Use of thiazole derivatives and analogues in the treatment of cancer |
| WO2008090356A1 (en) * | 2007-01-25 | 2008-07-31 | Betagenon Ab | Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity |
-
2010
- 2010-07-08 AU AU2010270030A patent/AU2010270030B2/en active Active
- 2010-07-08 SI SI201031157A patent/SI2451794T1/sl unknown
- 2010-07-08 DK DK10759940.9T patent/DK2451794T3/en active
- 2010-07-08 PL PL10759940T patent/PL2451794T3/pl unknown
- 2010-07-08 RS RS20160255A patent/RS54718B1/sr unknown
- 2010-07-08 SG SG2012001236A patent/SG177558A1/en unknown
- 2010-07-08 EA EA201200102A patent/EA026674B1/ru not_active IP Right Cessation
- 2010-07-08 HU HUE10759940A patent/HUE027263T2/en unknown
- 2010-07-08 JP JP2012519055A patent/JP5982281B2/ja active Active
- 2010-07-08 MX MX2012000441A patent/MX337516B/es active IP Right Grant
- 2010-07-08 CN CN201080030894.9A patent/CN102596923B/zh active Active
- 2010-07-08 NZ NZ597075A patent/NZ597075A/xx unknown
- 2010-07-08 ES ES10759940.9T patent/ES2567753T3/es active Active
- 2010-07-08 HR HRP20160353TT patent/HRP20160353T1/hr unknown
- 2010-07-08 US US13/381,426 patent/US9162994B2/en active Active
- 2010-07-08 BR BR112012000370-4A patent/BR112012000370B1/pt active IP Right Grant
- 2010-07-08 ME MEP-2016-66A patent/ME02443B/me unknown
- 2010-07-08 KR KR1020117030830A patent/KR101765957B1/ko active Active
- 2010-07-08 EP EP10759940.9A patent/EP2451794B1/en active Active
- 2010-07-08 WO PCT/GB2010/001315 patent/WO2011004162A2/en not_active Ceased
- 2010-07-08 CA CA2767291A patent/CA2767291C/en active Active
-
2011
- 2011-12-01 IL IL216723A patent/IL216723A/en active IP Right Grant
- 2011-12-05 ZA ZA2011/08901A patent/ZA201108901B/en unknown
-
2015
- 2015-10-14 US US14/883,190 patent/US9675596B2/en active Active
-
2016
- 2016-07-12 SM SM201600225T patent/SMT201600225B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX337516B (es) | Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer. | |
| MY161890A (en) | Pyrazolylaminopyridines as inhibitors of fak | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| TN2011000053A1 (en) | Organic compounds | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| IN2012DN00869A (es) | ||
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| MX2009007713A (es) | Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas. | |
| MX2010005109A (es) | Compuestos herbicidas. | |
| MX2009012418A (es) | Derivados de quinazolin-oxima como inhibidores de hsp90. | |
| MY145408A (en) | Dihydropyrazolopyrimidinone derivatives | |
| PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
| TW200740752A (en) | 4-Biarylyl-1-phenylazetidin-2-ones | |
| MX2009007482A (es) | Agentes antiparasitarios. | |
| DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| MY159183A (en) | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives | |
| ES2368594T3 (es) | Derivados sustituidos de ciclohexilmetilo. | |
| PA8792101A1 (es) | Nuevo procedimiento de sintesis del ( 7-metoxi-1- naftil) aceto | |
| MX2012007223A (es) | Carboxamidas fungicidas 2-(ariloxi biciclicas). | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| WO2008136378A1 (ja) | 新規なスルホンアミド誘導体またはその塩 | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| TW200616977A (en) | Enantiomers of selected fused heterocyclics and uses thereof | |
| EP2183256A4 (en) | THERAPEUTIC COMPOUNDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |